176 related articles for article (PubMed ID: 36983607)
1. Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line.
Pagani F; Gryzik M; Somenza E; Cominelli M; Balzarini P; Schreiber A; Mattavelli D; Nicolai P; Doglietto F; Poliani PL
J Pers Med; 2023 Feb; 13(3):. PubMed ID: 36983607
[TBL] [Abstract][Full Text] [Related]
2. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.
Han S; Polizzano C; Nielsen GP; Hornicek FJ; Rosenberg AE; Ramesh V
Clin Cancer Res; 2009 Mar; 15(6):1940-6. PubMed ID: 19276265
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Relevance and In Vitro Targeting of Concomitant PTEN and p16 Deficiency in Chordomas.
Seeling C; Mosca E; Mantel E; Möller P; Barth TFE; Mellert K
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046638
[TBL] [Abstract][Full Text] [Related]
4. Impact of CDK Inhibitors on
Bette S; Haase L; Nell J; Grieser T; von Baer A; Schultheiss M; Marienfeld R; Möller P; Barth TFE; Mellert K
Diagnostics (Basel); 2024 May; 14(10):. PubMed ID: 38786326
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity.
Batista KMP; Reyes KYA; Lopez FP; Pelaz AC; Vega IF; Pendás JLL; Ayala AS; Astudillo A; Rojas JAN; Fernandez PB
Contemp Oncol (Pozn); 2017; 21(4):267-273. PubMed ID: 29416431
[TBL] [Abstract][Full Text] [Related]
6. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.
Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H
Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608
[TBL] [Abstract][Full Text] [Related]
7. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
8. Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation.
O'donnell P; Tirabosco R; Vujovic S; Bartlett W; Briggs TW; Henderson S; Boshoff C; Flanagan AM
Skeletal Radiol; 2007 Jan; 36(1):59-65. PubMed ID: 16810540
[TBL] [Abstract][Full Text] [Related]
9. [Chordoma: is there a molecular basis for diagnosis and treatment?].
Scheipl S; Igrec J; Leithner A; Smolle M; Haybäck J; Liegl B
Pathologe; 2020 Mar; 41(2):153-162. PubMed ID: 32100085
[TBL] [Abstract][Full Text] [Related]
10. Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.
Lee DH; Zhang Y; Kassam AB; Park MJ; Gardner P; Prevedello D; Henry S; Horbinski C; Beumer JH; Tawbi H; Williams BJ; Shaffrey ME; Egorin MJ; Abounader R; Park DM
PLoS One; 2015; 10(8):e0134426. PubMed ID: 26247786
[TBL] [Abstract][Full Text] [Related]
11. Chordoma: the entity.
Yakkioui Y; van Overbeeke JJ; Santegoeds R; van Engeland M; Temel Y
Biochim Biophys Acta; 2014 Dec; 1846(2):655-69. PubMed ID: 25193090
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic targets in chordoma.
Bydon M; Papadimitriou K; Witham T; Wolinsky JP; Bydon A; Sciubba D; Gokaslan Z
Expert Opin Ther Targets; 2012 Nov; 16(11):1139-43. PubMed ID: 22860993
[TBL] [Abstract][Full Text] [Related]
13. Inhibition Of Glycogen Synthase Kinase 3 Beta Suppresses The Growth And Survival Of Skull Base Chordoma Cells By Downregulating Brachyury Expression.
Yan X; Li Z; Li H; Liu P; Zhao Z; Cheng S; Wang Z; Zhang Q
Onco Targets Ther; 2019; 12():9783-9791. PubMed ID: 31819479
[TBL] [Abstract][Full Text] [Related]
14. Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis.
Wen X; Cimera R; Aryeequaye R; Abhinta M; Athanasian E; Healey J; Fabbri N; Boland P; Zhang Y; Hameed M
Genes Chromosomes Cancer; 2021 Dec; 60(12):796-807. PubMed ID: 34392582
[TBL] [Abstract][Full Text] [Related]
15. Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma.
Kim JY; Lee J; Koh JS; Park MJ; Chang UK
J Neurosurg Spine; 2016 Nov; 25(5):626-635. PubMed ID: 27314550
[TBL] [Abstract][Full Text] [Related]
16. Loss of H3K27 trimethylation in a distinct group of de-differentiated chordoma of the skull base.
Makise N; Shimoi T; Sunami K; Aoyagi Y; Kobayashi H; Tanaka S; Kawai A; Yonemori K; Ushiku T; Yoshida A
Histopathology; 2023 Feb; 82(3):420-430. PubMed ID: 36217885
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
[TBL] [Abstract][Full Text] [Related]
18. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
19. Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma.
Schwab J; Antonescu C; Boland P; Healey J; Rosenberg A; Nielsen P; Iafrate J; Delaney T; Yoon S; Choy E; Harmon D; Raskin K; Yang C; Mankin H; Springfield D; Hornicek F; Duan Z
Anticancer Res; 2009 Jun; 29(6):1867-71. PubMed ID: 19528441
[TBL] [Abstract][Full Text] [Related]
20. UM-Chor1: establishment and characterization of the first validated clival chordoma cell line.
Owen JH; Komarck CM; Wang AC; Abuzeid WM; Keep RF; McKean EL; Sullivan S; Fan X; Prince MEP
J Neurosurg; 2018 Mar; 128(3):701-709. PubMed ID: 28430034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
